US · Healthcare · Biotechnology
EPS came in at -1.97 against a street estimate of -1.97 — a beat of 0.0%.
Analysts rate Moderna Inc a hold (6 buy, 17 hold, 4 sell out of 27) with an average price target of $49.47.
| Fund | Stake |
|---|---|
| FMR Inc | 11.51% |
| BlackRock Inc | 7.47% |
| Vanguard Capital Management, LLC | 5.76% |
| Baillie Gifford & Co Limited. | 5.04% |
| Capital World Investors | 4.71% |
| Vanguard Portfolio Management, LLC | 3.94% |
| State Street Corp | 3.75% |
| Geode Capital Management, LLC | 2.38% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-31 |
| Results announced · Q3 2026 | 2026-07-31 |
| Board / officer change · Q3 2026 | 2026-07-08 |
| Charter / bylaws change · Q2 2026 | 2026-05-11 |
| Quarterly report · Q1 2026 | 2026-05-01 |
| Results announced · Q2 2026 | 2026-05-01 |
| Proxy statement · Q2 2026 | 2026-03-16 |
| Annual report FY2025 | 2026-02-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Moderna Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.